Fig. 1From: Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrialsCONSORT diagram. EoT, end of therapy; ET, endocrine therapy; MRI, magnetic resonance imaging, pCR, pathological complete response; T-DM1, trastuzumab emtansine; US, ultrasoundBack to article page